Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  fulvestrant
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 44 for your search:
Start Over
A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6998L00004, NCT02447328
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBKM120F2303, 2012-002571-34, NCT01633060
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A011106, NCI-2013-01340, U10CA031946, NCT01953588
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15362, I3Y-MC-JPBL, 2013-004728-13, NCT02107703
Detect V / CHEVENDO (Chemo vs. Endo)
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and ove
Sponsor: Other
Protocol IDs: D-V, 2014-002249-22, NCT02344472
Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: Over 18, postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: GIM18-FUMANCE, NCT02383030
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over, postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: GIM16-FEVEX, NCT02404051
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over, postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011F2301, NCT02422615
SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over, postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO29058, 2014-003185-25, NCT02340221
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over, postmenopausal if female
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBYL719C2301, 2015-000340-42, NCT02437318
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FAKTION, NCT01992952
Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C31001, NCT02049957
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011X2108, NCT02088684
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H 20431, IRUSFULV0060, NCT00570323
Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: N08AFT, EudraCT; 2008-000644-13, NCT00738777
PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 45 and over
Sponsor: Other
Protocol IDs: PET/CT Breast, NCT00816582
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 84 and under
Sponsor: Other
Protocol IDs: CDR0000633329, IB-HORGEN, IB-IB2007-26, INCA-RECF0514, EUDRACT-2007-004216-31, ZENECA-IB-HORGEN, HORGEN, NCT00871858
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 11595, IRUSANAS0092, NCT00921115
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
Phase: Phase II
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: 2010-04-001, NCT01266213
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2210, 2011-001230-42, NCT01528345
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IFCT-1003, NCT01556191
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-477, NCT01560416
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PrE0102, NCT01797120
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: JBCRG-M04, NCT01989780
Start Over